Employees: 03 (2023.0)Legal category: Société à responsabilité limitée (sans autre indication)Size: PMECreation date: 1987-07-01 (38 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: LANGUEUX (22360), Cotes-d'Armor
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
EURL PHARMACIE PINCEMIN : revenue, balance sheet and financial ratios
EURL PHARMACIE PINCEMIN is a French company
founded 38 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in LANGUEUX (22360),
this company of category PME
shows in 2024 a net income positive of 173 k€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - EURL PHARMACIE PINCEMIN (SIREN 341951580)
Indicator
2024
2023
2022
2021
2020
2019
2017
2016
Revenue
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net income
173 303 €
223 470 €
208 320 €
216 991 €
214 832 €
204 825 €
211 632 €
253 177 €
EBITDA
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2024, EURL PHARMACIE PINCEMIN generates positive net income of 173 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2024: 253 k€ -> 173 k€.
Net income (2024)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
173 303 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 58%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 53%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2024)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
57.697%
Financial autonomy (2024)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
53.113%
Asset age ratio (2024)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2019
2020
2021
2022
2023
2024
Debt ratio
1.54
3.997
7.708
1.396
18.946
61.386
58.128
57.697
Financial autonomy
73.843
74.999
77.466
78.607
65.183
54.207
55.105
53.113
Repayment capacity
None
None
None
None
None
None
None
None
Cash flow / Revenue
None%
None%
None%
None%
None%
None%
None%
None%
Sector positioning
Debt ratio
57.72024
2022
2023
2024
Q1: 16.45
Med: 58.41
Q3: 154.59
Good+6 pts over 3 years
In 2024, the debt ratio of EURL PHARMACIE PINCEMIN (57.70) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
Financial autonomy
53.11%2024
2022
2023
2024
Q1: 28.92%
Med: 49.95%
Q3: 69.49%
Good-5 pts over 3 years
In 2024, the financial autonomy of EURL PHARMACIE PINCEMIN (53.1%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 271.15. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2024)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2016
2017
2019
2020
2021
2022
2023
2024
Liquidity ratio
179.52
183.756
221.521
178.37
166.976
275.347
291.796
271.155
Interest coverage
None
None
None
None
None
None
None
None
Sector positioning
Liquidity ratio
271.152024
2022
2023
2024
Q1: 129.47
Med: 182.14
Q3: 260.79
Excellent
In 2024, the liquidity ratio of EURL PHARMACIE PINCEMIN (271.15) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
Positioning of EURL PHARMACIE PINCEMIN in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 225 transactions of similar company sales
in 2024,
the value of EURL PHARMACIE PINCEMIN is estimated at
2 419 438 €
(range 1 684 858€ - 3 619 617€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2024
225 transactions
1684k€2419k€3619k€
2 419 438 €Range: 1 684 858€ - 3 619 617€
NAF 5 année 2024
Valuation method used
Net Income Multiple
173 303 €
×
14.0x
=2 419 438 €
Range: 1 684 858€ - 3 619 618€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare EURL PHARMACIE PINCEMIN with other companies in the same sector:
Frequently asked questions about EURL PHARMACIE PINCEMIN
What is the revenue of EURL PHARMACIE PINCEMIN ?
The revenue of EURL PHARMACIE PINCEMIN is not publicly disclosed (confidential accounts filed with INPI).
Is EURL PHARMACIE PINCEMIN profitable?
Yes, EURL PHARMACIE PINCEMIN generated a net profit of 173 k€ in 2024.
Where is the headquarters of EURL PHARMACIE PINCEMIN ?
The headquarters of EURL PHARMACIE PINCEMIN is located in LANGUEUX (22360), in the department Cotes-d'Armor.
Where to find the tax return of EURL PHARMACIE PINCEMIN ?
The tax return of EURL PHARMACIE PINCEMIN is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does EURL PHARMACIE PINCEMIN operate?
EURL PHARMACIE PINCEMIN operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart